PPARGC1A and myocardial infarction: As shown in Fig. 3B, C and Supplementary Fig. S8A, B, PGC1α levels were significantly increased in the VNS-treated hearts compared with MI hearts, and these favorable effects could markedly be abolished by mACh-R and α7-nAChR inhibitors.